Fmoc-D-Cha-OH: Quality You Can Trust from the Manufacturer

In peptide chemistry, choices made at the raw materials stage ripple throughout the process. At our plant, we have witnessed the impact of each building block long before it becomes part of a research breakthrough or clinical milestone. Fmoc-D-Cyclohexylalanine (abbreviated as Fmoc-D-Cha-OH), with CAS Number 132210-23-4, serves as one of the unique foundations for constructing advanced peptides due to its structure and stereochemistry. Having produced this compound for over a decade, we understand not just how it is made, but why its details matter.

Unpacking Fmoc-D-Cha-OH

This product does not belong to the realm of commodity amino acids. It carries a cyclohexyl group on a D-configuration amino acid backbone, protected at the N-terminus with an Fmoc group. In the solid-phase peptide synthesis (SPPS) field, Fmoc-protected amino acids like this one serve a clear function: providing both orthogonal protection and robust resistance to racemization during coupling and deprotection cycles.

With each lot produced here, we test not just purity via HPLC, but also impurities specific to cyclohexyl derivatives. Instead of aiming only for a high percentage value, attention falls upon completeness of Fmoc blocking, optical rotation, and residual side products, since even the smallest impurity can introduce side reactions in chain elongation or cause diminished yield for our customers.

Why D-Cha Matters for Peptide Synthesis

Many working in peptide R&D gravitate toward L-amino acids out of habit, but D-amino acids tell a different story inside a finished peptide. D-Cha introduces pronounced resistance to enzymatic degradation, improves membrane permeability in bioactive peptides, and influences secondary structure. Cyclohexylalanine's bulky nature drives the formation of β-turns and shields sensitive regions of peptide chains. Over the years, we have worked closely with teams designing antimicrobial peptides, receptor antagonists, and enzyme inhibitors, where one substitution can change the lifetime and selectivity of a peptide in a biological setting.

Differences from Other Fmoc-Protected Amino Acids

Some compare Fmoc-D-Cha-OH to more common Fmoc-L-Cha-OH, or to Fmoc-protected valine or leucine analogues, assuming interchangeability. D- and L- isomers are not equivalents in advanced synthesis—the body recognizes each differently, so structure-function relationships diverge quickly. The D-configuration means resistance to endogenous proteases, making your product last longer in a biological assay or test system. Cyclohexylalanine, as a nonproteinogenic amino acid, brings lipophilicity that is absent from Fmoc-Leu-OH or Fmoc-Val-OH. This property changes solubility, aggregation, and interactions within drug candidates or research probes.

From a chemical manufacture perspective, D-isomers can present unexpected risks: unwanted racemization during activation. We keep our synthetic route and purification steps tightly controlled, using only fresh, high-purity starting chemicals, since process drift produces mixed stereochemistry. A few percentage points of L-impurity can thoroughly compromise the effect of D-Cha in your peptide. Regular feedback with academic researchers and diagnostic kit developers keeps us alert to the ways stereochemistry drives function downstream.

Specifications That Are More Than a Number

Some people ask for “specs” with the assumption that all options meeting those numbers are fungible. In industrial chemistry, data points like purity (>98.0% HPLC), Fmoc content, and enantiomeric excess (ees above 99%) each have a story behind them. For Fmoc-D-Cha-OH, a clear, white to off-white crystalline powder is the standard; each batch passes multiple checks for Fmoc group integrity, water content (Karl Fischer titration below 1.0%), and residual solvent (GC traceable below the ICH thresholds). It isn’t just aesthetics—we validate that each lot dissolves readily in DMF, DCM, and other common SPPS solvents, and carries no latent traces of unreacted starting material. When scale-up is required, process troubleshooting draws on years of incremental improvements: tiny changes in temperature or stirring speed influence both yield and impurity profile.

Common Applications and Customer Needs

Fmoc-D-Cha-OH gets incorporated into peptide chains using standard Fmoc-based solid phase protocols. We have supplied clients working on complex cyclic peptides, peptidomimetics intended for cancer and infectious disease research, and library synthesis for structure-activity relationship studies. Every year, batch requests for D-configured amino acids have risen, often driven by a need for metabolic stability without altering critical biological interactions. Functional roles span signal transduction studies, substrate design for protease activity profiling, and even biosensor projects where the non-canonical sidechain offers chemical handles unavailable in natural amino acids.

Our collaboration with university researchers and pharmaceutical innovators brings regular feedback on why purity and stereo-integrity affect real outcomes. In one project, a team screening synthetic analogues for antimicrobial activity found that even 2% L-epimer contamination dropped activity indices by almost a third. Another group, designing enzyme-resistant hormone mimetics, required D-Cha substitutions to stop rapid degradation by human serum proteases; small spectral impurities triggered reproducibility challenges. These examples teach us to align every manufacturing step to the ultimate application, not just “spec” compliance.

What Sets True Manufacturer Product Apart

Direct manufacturing pushes us to refine not only chemistry, but also transparency. We don’t rely on repackaged material or opaque sourcing; control rests in-house, making traceability possible from raw precursors to final lot. Our plant’s QA team reviews every HPLC trace, NMR spectrum, and chiral analysis in real time—access to these records is open to customers with technical questions. In contrast, generic suppliers and traders may handle inventory with less process data, so buyers risk latent issues surfacing during synthesis or QC.

Experience over the years shows that “grade” alone is an incomplete promise. Customs often ask for assurance on batch consistency over quarterly or annual contracts. Our answer comes from regular side-by-side comparisons, retaining a sample from every campaign for back-testing. Fmoc-D-Cha-OH must not just pass initial analysis, but must remain stable during shipping, storage, and downstream handling—our packaging (airtight, moisture-proof) adapts to this.

Working closely with custom peptide companies, we note issues that crop up not in storage, but in real-time synthesis—such as aggregation problems, solubility hiccups, or coupling failures linked back to trace byproducts. Fixing these means addressing root process variables rather than masking outliers. On-site technical support includes helping interpret unexpected HPLC peaks, troubleshooting reaction failures, and adjusting solvent protocols if environmental conditions or pH unexpectedly influence chain elongation.

Differences in Sourcing: Manufacturer Experience

Direct chemistry manufacturing does not follow shortcuts that are common in trading. We synthesize Fmoc-D-Cha-OH starting from D-Cha, undergo established coupling and protection reactions, keep batch-time analytics tight, and finish with careful drying and bottling. Sourcing from direct producers means the technical team can answer compound-specific questions, whether it’s about reactivity, dissolution, or why a synthesis failed even when using nominally high-purity input. Over the years, we have had customers bring in products acquired from resellers that failed due to latent racemization or contamination—preventable with full-process oversight.

Comparison between D- and L- forms isn't trivial. Analytical tools at our site allow for precise measurement of enantiomer ratio, ensuring absence of cross-contamination. Research groups looking to study chirality-driven function routinely ask for alignment with spectroscopic (CD, NMR), chromatographic, and optical rotation benchmarks. Our response has always been to supply test vials, invite comparative method runs, and stand by the process data for every claim made.

Solving Problems for Research and Production

In the field, peptide synthesis rarely follows a “plug-and-play” path. Newcomers sometimes expect that D-amino acids behave like their L-counterparts, only to run into coupling inefficiencies or downstream purification challenges. We maintain a technical library drawn from both academic publications and customer experience, ready to suggest alternate coupling reagents or solvent combinations. Adjusting for steric hindrance or optimizing chain extension cycles with Fmoc-D-Cha-OH becomes crucial when project timelines tighten.

Another issue customers see involves facility adaptation to scale. Lab-scale reactions often scale poorly; solvent ratios, mixing times, or temperature gradients can expose previously undetected lot variability. Running in-house pilot syntheses with our sample lots ensures compatibility before a full batch commitment. Only by producing Fmoc-D-Cha-OH directly do we track changes in impurity profile as scale increases—our site data confirms that careful solvent removal, lower residual acid number, and faster quenching reduce side product carryover.

Compliance, Documentation, and Safety

Researchers in regulated industries require evidence for each step, both for internal QC and for meeting external audit requirements. Supplied with a full range of documentation—COAs with batch-specific test data, method protocols, and frequently up-to-date elemental analyses—customers rely on verifiable transparency. Internal QC does not stop at generic limits, but includes analysis of organics content, chiral purity, moisture, and UV-spectra to flag possible anomalies early.

Our facility follows all relevant guidelines for handling amino acid derivatives, not only to protect the product, but to assure reliability across borders. Packaging integrity gets verified, labeling matches IUPAC standards, and transport partners stay updated to minimize storage risks en route to research facilities.

Collaborative Evolution of the Product

As Fmoc-D-Cha-OH’s role in research evolves, new challenges and applications surface. In the past five years, demand has shifted dramatically—no longer limited to early-stage discovery, pharmaceutical-scale plans for clinical peptides now call for kilogram quantities. In scaling up, issues like heat transfer, mixing efficiency, and batch reactor control surface, raising novel quality questions. By owning the production workflow, we implement changes quickly, vetting adjustments directly instead of relying on off-site suppliers.

Working directly with leading biotech groups, we incorporate feedback loops into our production. Subtle shifts in process control, such as fine-tuning Fmoc deprotection conditions, feed directly into upgrades that make the end product more robust for SPPS. Failures and bottlenecks get dissected not only in our lab, but in our technical support communication. This culture of direct response and learning ensures the integrity of future lots and maintains the level of reliability required for high-stakes, expensive research.

Continued Value for Peptide Researchers

Many in the field start out looking for the lowest price or fastest delivery, but seasoned researchers return to suppliers who can demonstrate consistent, controlled manufacture. Repeat customers—ranging from pharmaceutical scale-up teams to university principal investigators—cite not just product performance, but access to firsthand insight and ready technical troubleshooting. With Fmoc-D-Cha-OH, our team acts as both manufacturer and ongoing support partner, bringing applied chemistry expertise to every challenge that arises, from bench to batch.

We recognize that finding the right protected amino acid includes more than specification sheets; subtle variations influence ultimate success. Through hands-on production, continual dialogue with end-users, and rigorous quality benchmarks, Fmoc-D-Cha-OH becomes more than just a catalog entry. For peptide innovators, every successful project that incorporates our material is a shared success—and the basis for tomorrow’s new methods, molecules, and discoveries.

Looking Forward: Partnering for Innovation

We see research as a collaboration. New projects bring unfamiliar substitutions, tough-to-couple chains, or process scale-ups that stretch known approaches. Each advance in peptide design using Fmoc-D-Cha-OH reflects the intricate dance between solid chemical manufacturing and creative scientific effort. Our aim as manufacturer is to keep our process open, our documentation comprehensive, and our technical advice grounded in daily practice.

Fmoc-D-Cha-OH, with its unique blend of cyclohexyl bulk, D-stereochemistry, and reliable Fmoc protection, continues to support researchers at the edge of discovery. Our experience—direct, on-the-ground, and ever evolving—gives us the vantage point to not only supply, but to lift science forward, one compound at a time.